Compare Aurora Cannabis Inc (ACB) vs Docusign Inc (DOCU) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

DOCU trades at $47.23, up 3.19% with a bullish technical signal. Recent earnings consistently beat expectations, with Q1 2026 EPS of $1.09 exceeding estimates. Revenue growth remains steady, reaching $2.98B in 2025, while profitability improved significantly with a net income margin of 35.87%. The company's partnerships with Perplexity and Slack highlight ongoing innovation in agreement management workflows, supporting future growth prospects amid positive analyst sentiment.

The outlook for DOCU is cautiously optimistic, with a consensus price target of $55.40 suggesting 17% upside. Key opportunities include expanding AI integration and enterprise adoption, but risks involve competitive pressures and reliance on subscription revenue stability. Valuation metrics like a P/E of 30.45 require sustained earnings growth to justify current levels, making execution critical for shareholder returns.